123 related articles for article (PubMed ID: 20575024)
41. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma.
Barth TF; Martin-Subero JI; Joos S; Menz CK; Hasel C; Mechtersheimer G; Parwaresch RM; Lichter P; Siebert R; Möoller P
Blood; 2003 May; 101(9):3681-6. PubMed ID: 12511414
[TBL] [Abstract][Full Text] [Related]
42. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
43. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
44. Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK?
Morgenstern DA; Soh SY; Stavropoulos DJ; Bowdin S; Baruchel S; Malkin D; Meyn MS; Irwin MS
J Pediatr Hematol Oncol; 2014 Apr; 36(3):e193-6. PubMed ID: 24276038
[TBL] [Abstract][Full Text] [Related]
45. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
46. Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells.
Sugihara E; Kanai M; Matsui A; Onodera M; Schwab M; Miwa M
Oncogene; 2004 Jan; 23(4):1005-9. PubMed ID: 14647433
[TBL] [Abstract][Full Text] [Related]
47. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.
Munzert G; Kirchner D; Stobbe H; Bergmann L; Schmid RM; Döhner H; Heimpel H
Blood; 2002 Nov; 100(10):3749-56. PubMed ID: 12411322
[TBL] [Abstract][Full Text] [Related]
48. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
49. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
[TBL] [Abstract][Full Text] [Related]
50. [Transcription levels of the MYCN gene in blood cell subpopulations of Patients with leukemia].
Malakho SG; Nikitin EA; Nasedkina TV; Poltaraus AB
Mol Biol (Mosk); 2008; 42(2):378-82. PubMed ID: 18610847
[No Abstract] [Full Text] [Related]
51. c-myc and K-ras-2 oncogenes in B-cell chronic lymphocytic leukemia with del(12)(p13).
Wang TY; Samples DM; Dabdoub R; Prakash O
Cancer Genet Cytogenet; 1991 Jan; 51(1):125-30. PubMed ID: 1984840
[TBL] [Abstract][Full Text] [Related]
52. The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.
Eide HA; Halvorsen AR; Bjaanæs MM; Piri H; Holm R; Solberg S; Jørgensen L; Brustugun OT; Kiserud CE; Helland Å
BMC Cancer; 2016 Feb; 16():71. PubMed ID: 26858029
[TBL] [Abstract][Full Text] [Related]
53. MYCNOS functions as an antisense RNA regulating MYCN.
Vadie N; Saayman S; Lenox A; Ackley A; Clemson M; Burdach J; Hart J; Vogt PK; Morris KV
RNA Biol; 2015; 12(8):893-9. PubMed ID: 26156430
[TBL] [Abstract][Full Text] [Related]
54. Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia.
McKeithan TW; Ohno H; Diaz MO
Genes Chromosomes Cancer; 1990 Jan; 1(3):247-55. PubMed ID: 2083219
[TBL] [Abstract][Full Text] [Related]
55. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
56. MycN is a transcriptional regulator of livin in neuroblastoma.
Dasgupta A; Peirce SK; Findley HW
Oncol Rep; 2009 Oct; 22(4):831-5. PubMed ID: 19724862
[TBL] [Abstract][Full Text] [Related]
57. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
58. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
59. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.
Watanabe T; Hotta T; Ichikawa A; Kinoshita T; Nagai H; Uchida T; Murate T; Saito H
Blood; 1994 Nov; 84(9):3158-65. PubMed ID: 7949188
[TBL] [Abstract][Full Text] [Related]
60. Integrated cytogenetic and high-resolution array CGH analysis of genomic alterations associated with MYCN amplification.
Pandita A; Bayani J; Paderova J; Marrano P; Graham C; Barrett M; Prasad M; Zielenska M; Squire JA
Cytogenet Genome Res; 2011; 134(1):27-39. PubMed ID: 21508638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
